Get the Stockscreener App
19.63
0.31%
0.06
After Hours:
19.64
0.01
+0.05%
Nuvectis Pharma Inc stock is traded at $19.63, with a volume of 572.42K.
It is up +0.31% in the last 24 hours and up +105.77% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$19.57
Open:
$20.57
24h Volume:
572.42K
Relative Volume:
2.77
Market Cap:
$520.70M
Revenue:
-
Net Income/Loss:
$-29.59M
P/E Ratio:
-15.40
EPS:
-1.275
Net Cash Flow:
$-18.35M
1W Performance:
-31.20%
1M Performance:
+105.77%
6M Performance:
+139.39%
1Y Performance:
+160.34%
1-Day Range:
$19.61
$20.74
1-Week Range:
$17.77
$21.24
52-Week Range:
$5.55
$29.27
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
19.63 | 487.80M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Nuvectis Pharma announces public share offering to support drug programs - MSN
Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvect - GuruFocus
Nuvectis Pharma CEO Ron Bentsur buys $250,000 in company stock By Investing.com - Investing.com South Africa
[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity - Stock Titan
Form 4 Nuvectis Pharma Inc For: 1 July By Investing.com - Investing.com India
Nuvectis Pharma 10% owner Mosseri buys $916k in shares - Investing.com UK
Nuvectis Pharma (NVCT) CEO Ron Bentsur buys $250,000 in shares - Stock Titan
Nuvectis: 'Hold' On NXP800 Removal And Newly Licensed Candidates (NASDAQ:NVCT) - Seeking Alpha
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Nuvectis Raises $100M for Oncology Pivot - AllSci
Nuvectis Pharma Announces Major Public Equity Offering - TipRanks
Form 424B5 Nuvectis Pharma Inc For: 30 June By Investing.com - Investing.com Canada
Nuvectis Pharma Sets 5M-Share, $20 Offering; ~$93M Net, Cantor Fitzgerald Underwriter - TradingView
Nuvectis Pharma (NASDAQ: NVCT) to raise $100M in stock sale - Stock Titan
Nuvectis Pharma (NVCT) files $100M offering; 5.0M shares at $20.00 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Nuvectis gains two experimental drugs in licensing deal with China's Haisco - MSN
Nuvectis shares continue to rally after $1.46B Haisco deal - BioWorld News
Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT) - Yahoo Finance
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stoc - Benzinga
Nuvectis Pharma stock tumbles 25% on discounted offering By Investing.com - Investing.com Canada
Nuvectis Pharma Prices $100 Million Secondary Stock Offering; Shares Down Pre-Bell - Moomoo
Nuvectis Pharma's $100 Million Offering: Dilution at a Discount Amidst Pipeline Hopes - Kavout | AI
Nuvectis locks in $100M from 5 million-share stock sale - Stock Titan
Nuvectis Pharma Intends to Use Net Proceeds From Offering to Advance Development Programs >NVCT - Moomoo
Nuvectis Pharma prices $100 million public offering at $20/share By Investing.com - Investing.com Australia
Nuvectis Pharma Prices $100 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock - GlobeNewswire
Form 424B5 Nuvectis Pharma Inc For: 29 June - Investing.com UK
Form 424B5 Nuvectis Pharma Inc For: 29 June By Investing.com - Investing.com Australia
Nuvectis Pharma launches public offering of common stock By Investing.com - Investing.com Australia
Nuvectis Pharma stock tumbles on public offering launch By Investing.com - Investing.com South Africa
Nuvectis Pharma prices $100 million public offering of common stock - scanx.trade
Nuvectis Pharma Suspends Equity Offering Program Under Agreement - TipRanks
Nuvectis (NASDAQ: NVCT) prelim prospectus; Haisco license, $20M upfront - Stock Titan
Nuvectis Pharma launches public offering of common stock - Investing.com
Nuvectis Pharma Launches Proposed Public Stock Offering - Moomoo
Nuvectis Pharma stock tumbles on public offering launch - Investing.com UK
Nuvectis Pharma moves to raise capital through proposed public stock sale - Traders Union
Nuvectis Pharma (NASDAQ: NVCT) cuts and suspends $5M ATM share sales - Stock Titan
Nuvectis Pharma seeks fresh capital for cancer and immune programs - Stock Titan
Nuvectis Pharma, Inc.(NasdaqCM: NVCT) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Nuvectis Pharma Up 97%, Insider Buyers Are Up 344% - simplywall.st
Enterprise value to revenue forward of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
Enterprise value to EBIT forward of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
Price to book forward of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
What makes Nuvectis Pharma (NVCT) a new buy stock - MSN
What Makes Nuvectis Pharma (NVCT) a New Buy Stock - Yahoo Finance
Nuvectis Pharma, Inc. Actuals & Estimates (NASDAQ:NVCT) - TradingView
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - MSN
NVCT Forecast — Price Target — Prediction for 2027 - TradingView
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
Jun 30 '26 |
Buy |
20.00 |
12,500 |
250,000 |
3,688,424 |
| BENTSUR RON | Chairman & CEO |
Nov 05 '25 |
Buy |
5.72 |
5,000 |
28,600 |
3,525,924 |
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):